MCC950
10mM in DMSO
- Product Code: 204453
CAS:
210826-40-7
| Molecular Weight: | 404.48 g./mol | Molecular Formula: | C₂₀H₂₄N₂O₅S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
MCC950 is a potent and selective inhibitor of the NLRP3 inflammasome, a key component of the innate immune system involved in the production of pro-inflammatory cytokines like IL-1β and IL-18. Its primary application lies in research on inflammatory diseases where NLRP3 activation plays a critical role.
It is widely used in preclinical studies to investigate conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), where neuroinflammation contributes to disease progression. In metabolic disorders, MCC950 has shown promise in models of type 2 diabetes and atherosclerosis by reducing inflammation in adipose tissue and arterial plaques.
In autoimmune and autoinflammatory diseases, including gout and Muckle-Wells syndrome, MCC950 effectively blocks inflammasome-driven inflammation, leading to reduced symptoms in animal models. It has also been explored in ischemia-reperfusion injury, such as myocardial infarction and stroke, where it helps limit tissue damage by suppressing inflammatory responses after blood flow restoration.
Due to its ability to cross cell membranes and its oral bioavailability in animal models, MCC950 is a valuable tool compound for validating the therapeutic potential of NLRP3 inhibition. However, it remains primarily a research chemical and has not been approved for clinical use in humans.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿6,480.00 |
+
-
|
MCC950
MCC950 is a potent and selective inhibitor of the NLRP3 inflammasome, a key component of the innate immune system involved in the production of pro-inflammatory cytokines like IL-1β and IL-18. Its primary application lies in research on inflammatory diseases where NLRP3 activation plays a critical role.
It is widely used in preclinical studies to investigate conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), where neuroinflammation contributes to disease progression. In metabolic disorders, MCC950 has shown promise in models of type 2 diabetes and atherosclerosis by reducing inflammation in adipose tissue and arterial plaques.
In autoimmune and autoinflammatory diseases, including gout and Muckle-Wells syndrome, MCC950 effectively blocks inflammasome-driven inflammation, leading to reduced symptoms in animal models. It has also been explored in ischemia-reperfusion injury, such as myocardial infarction and stroke, where it helps limit tissue damage by suppressing inflammatory responses after blood flow restoration.
Due to its ability to cross cell membranes and its oral bioavailability in animal models, MCC950 is a valuable tool compound for validating the therapeutic potential of NLRP3 inhibition. However, it remains primarily a research chemical and has not been approved for clinical use in humans.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :